Ensysce Biosciences believes it regains Nasdaq stockholders' equity compliance after warrant exercise

Ensysce Biosciences, Inc.

Company believes it now has at least $2.5M stockholders' equity, satisfying Nasdaq listing rule.
February 2024 warrant exercise generated gross proceeds of ~$4.7M.
Previously received Nasdaq extension to May 13, 2024 to evidence compliance.
Awaiting Nasdaq formal confirmation of compliance status.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.